PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Location: France, Auvergne-Rhône-Alpes, Lyon
Investors 1
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
Mentions in press and media 12
| Date | Title | Description |
| 18.11.2024 | PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" | PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the ... |
| 13.11.2024 | PHAXIAM Reports Third-Quarter 2024 Financial Information | Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon (France), November 13, 2024, at 5:45 p.... |
| 04.11.2024 | PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. | GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureus The clinical protocol also being submitted to the European health authorities and the MHRA in the UK... |
| 09.10.2024 | PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study | A Phase 2 study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM’s anti-S. aureus phages added to the sta... |
| 25.09.2024 | PHAXIAM Provides Business and Financial Update For the First Half of 2024 | Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic Joint Infections (PJI) strategic prog... |
| 27.06.2024 | PHAXIAM Therapeutics annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription de 7,8 M€ | Lyon (France), le 27 juin 2024 - 17h45 CEST - PHAXIAM Therapeutics (la « Société »), société biopharmaceutique qui développe des traitements innovants contre les infections bactériennes sévères et résistantes, annonce le succès de son augme... |
| 12.06.2024 | Lancement d'une augmentation de capital avec maintien du DPS d’un montant d’environ 10 M€, susceptible d’être porté à environ 11,5 M€ en cas d’exercice intégral de la clause d'extension... | Ne pas publier, distribuer ou circuler, directement ou indirectement, aux Etats-Unis d’Amérique, au Canada, en Australie, en Afrique du Sud ou au Japon. Le présent communiqué constitue une communication à caractère promotionnel et non pas u... |
| 11.03.2024 | PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market | - |
| 20.02.2024 | PHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital Market | PHAXIAM reste cotée sur Euronext Paris, son marché principal Le retrait de la cote du Nasdaq réduira considérablement la consommation de trésorerie de PHAXIAM et permettra à la Société de concentrer ses ressources financières sur les étapes... |
| 20.02.2024 | PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market | PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading market Nasdaq delisting will significantly reduce PHAXIAM... |
Show more